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ABSTRACT
Background: It is well established that low birth weight and accel-
erated postnatal growth increase the risk of liver dysfunction in later
life. However, molecular mechanisms underlying such developmen-
tal programming are not well characterized, and potential interven-
tion strategies are poorly defined.
Objectives: We tested the hypotheses that poor maternal nutrition
and accelerated postnatal growth would lead to increased hepatic
fibrosis (a pathological marker of liver dysfunction) and that post-
natal supplementation with the antioxidant coenzyme Q10 (CoQ10)
would prevent this programmed phenotype.
Design: A rat model of maternal protein restriction was used to
generate low-birth-weight offspring that underwent accelerated post-
natal growth (termed “recuperated”). These were compared with con-
trol rats. Offspring were weaned onto standard feed pellets with or
without dietary CoQ10 (1 mg/kg body weight per day) supplementa-
tion. At 12 mo, hepatic fibrosis, indexes of inflammation, oxidative
stress, and insulin signaling were measured by histology, Western
blot, ELISA, and reverse transcriptase–polymerase chain reaction.
Results: Hepatic collagen deposition (diameter of deposit) was
greater in recuperated offspring (mean 6 SEM: 12 6 2 mm) than
in controls (5 6 0.5 mm) (P , 0.001). This was associated with
greater inflammation (interleukin 6: 38% 6 24% increase; P ,
0.05; tumor necrosis factor a: 64% 6 24% increase; P , 0.05),
lipid peroxidation (4-hydroxynonenal, measured by ELISA: 0.30 6
0.02 compared with 0.19 6 0.05 mg/mL per mg protein; P , 0.05),
and hyperinsulinemia (P , 0.05). CoQ10 supplementation increased
(P , 0.01) hepatic CoQ10 concentrations and ameliorated liver
fibrosis (P , 0.001), inflammation (P , 0.001), some measures
of oxidative stress (P , 0.001), and hyperinsulinemia (P , 0.01).
Conclusions: Suboptimal in utero nutrition combined with acceler-
ated postnatal catch-up growth caused more hepatic fibrosis in
adulthood, which was associated with higher indexes of oxidative
stress and inflammation and hyperinsulinemia. CoQ10 supplemen-
tation prevented liver fibrosis accompanied by downregulation of
oxidative stress, inflammation, and hyperinsulinemia. Am J
Clin Nutr 2016;103:579–88.
Keywords: developmental programming, liver disease, coenzyme Q,
low birth weight, accelerated postnatal growth
INTRODUCTION
In 1992, Hales and Barker (1) proposed the “thrifty phenotype
hypothesis,” which postulated that in response to suboptimal in
utero nutrition, the fetus alters its organ structure and adapts its
metabolism to ensure immediate survival. This occurs through
the sparing of vital organs (e.g., the brain) at the expense of
others, such as the liver, thus increasing the risk of metabolic
disease such as liver dysfunction in later life (2–4). This risk is
exacerbated if a suboptimal uterine environment is followed by
rapid postnatal growth (5, 6).
Nonalcoholic fatty liver disease (NAFLD)4 is the hepatic
manifestation of the metabolic syndrome. Aspects of the meta-
bolic syndrome, including NAFLD, have been linked to expo-
sure to suboptimal early-life environments (7, 8). Although the
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CoQ9, coenzyme Q isoform containing 9 isoprenoid units; CoQ10, coenzyme
Q; CYP2E1, cytochrome P450-2E1; Des, desmin; EC, Enzyme Commission;
Gfap, glial fibrillary acidic protein; Gpx1, glutathione peroxidase 1; Gst,
glutathione synthetase; Hmox1, heme oxygenase 1; HSC, hepatic stellate
cell; IR-b, insulin receptor b; IRS-1, insulin receptor substrate 1; KC, Kupffer
cell;Mcp1, monocyte chemoattractant protein 1;Mmp, matrix metalloproteinase;
NAFLD, nonalcoholic fatty liver disease; NOX-2, NAD(P)H oxidase 2; Nqo1,
NAD(P)H dehydrogenase, quinone 1; Nrf2, nuclear factor, erythroid 2–like 2;
p85-a, phosphoinositide-3-kinase, p85-a; p110-b, phosphoinositide-3-kinase,
p110-b; ROS, reactive oxygen species; Tgfb1, transforming growth factor b1;
Timp, tissue inhibitor of matrix metalloproteinases; 4-HNE, 4-hydroxynonenal.
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incidence of NAFLD is high (9), the associated morbidity is low
if there is no progression to hepatic fibrosis. Progression to fi-
brosis is indicative of the clinically important subtype of patients
with NAFLD who have a high chance (20%) of developing frank
liver cirrhosis and subsequent liver failure (10). At present, it
is unknown why this progression occurs only in a subset of
individuals. The development of an intervention that prevents
these changes from accumulating could improve the prognosis
of patients who develop NAFLD later in life.
Increased oxidative stress is a common consequence of de-
velopmental programming (11). Increased reactive oxygen
species (ROS) have been strongly implicated in the etiology of
hepatic fibrosis. Several animal studies have focused on anti-
oxidant therapies to prevent the deleterious phenotypes of de-
velopmental programming (12–14); however, the doses used are
not recommended for use in humans. In practice, a suboptimal
intrauterine environment is often recognized retrospectively (i.e.,
after delivery). Thus, it is important to address potential bene-
ficial effects of targeted postnatal interventions.
Coenzyme Q (CoQ10) is a benzoquinone ring linked to an
isoprenoid side-chain. The isoform containing 9 isoprenoid units
(CoQ9) is most abundant in rodents, whereas CoQ10 (10 iso-
prenoid units) is the most common in humans. When oxidized,
CoQ10 shuttles electrons between mitochondrial complexes I
and III and complexes II and III. Reduced CoQ10 is the most
abundant endogenous cellular antioxidant (15) and is a safe and
effective therapeutic antioxidant (16, 17). We have also shown
that postnatal CoQ10 supplementation prevents developmentally
programmed accelerated aging in rat aortas (18) and hearts (19).
Liver is one of a few tissues to take up dietary CoQ10 (20), and
CoQ10 supplementation has been previously investigated as
a potential therapy to prevent the progression of NAFLD in
humans (21). In this study, we aimed to 1) investigate the effects
of poor maternal nutrition and rapid postnatal catch-up growth
on hepatic CoQ9 concentrations and molecular pathways leading
to proinflammatory changes and development of fibrosis and 2)
determine whether a clinically relevant dose of dietary CoQ10
could correct any observed hepatic fibrosis.
METHODS
Animal experimentation
All procedures involving animals were conducted under the
British Animals (Scientific Procedures) Act (1986) and un-
derwent ethical review by the University of Cambridge Animal
Welfare and Ethical Review Board. Stock animals were pur-
chased from Charles River, and dams were produced from in-
house breeding from stock animals.
Pregnant Wistar rats were maintained at room temperature
in specific-pathogen-free housing with the use of individually
ventilated cages with environmental enrichment. The dams were
maintained on a 20% protein diet (control) or an isocaloric low-
protein (8%) diet, as previously described (22). Access to diets
and water was provided ad libitum. All rats used in this study
were specific-pathogen-free housed individually at 228C on a
controlled 12:12-h light-dark cycle. Diets were purchased from
Arie Blok.
The day of birth was recorded as day 1 of postnatal life. Pups
born to low-protein-diet–fed dams were cross-fostered to con-
trol-fed mothers on postnatal day 3 to create a recuperated litter.
Each recuperated litter was standardized to 4 male pups at
random to maximize their plane of nutrition. The control group
consisted of the offspring of dams fed the 20%-protein diet and
suckled by 20% protein–fed dams. Each control litter was culled
to 8 pups as a standard. To minimize stress to the pups when
cross-fostered, they were transferred with some of their own
bedding. Body weights were recorded at postnatal days 3 and 21
and at 12 mo. At 21 d, 2 males per litter were weaned onto
standard laboratory feed pellets (Special Diet Services) and the
other 2 were weaned onto the same diet supplemented with
CoQ10 to give a dose of 1 mg/kg body weight per day. Diets
were given in the home cage. Rat pups were fed these diets until
12 mo of age, at which time all rats were killed by carbon di-
oxide asphyxiation at w1000. Post mortem, liver tissue was
removed, weighed, and snap-frozen in liquid nitrogen and then
stored at 2808C until analysis. A further portion of liver tissue
(the same area for each sample) was removed and fixed in for-
malin for histologic assessment.
For all measurements, 1 pup per litter was used, thus “n”
represents number of litters. Ten litters per group were used in
this study based on power calculation with the use of previous
data from our studies of RNA expression in postnatal tissues
from programmed animals. Rat numbers were calculated to give
80% power to detect a 20% difference between groups at the
P , 0.05 level. Only male rats were used in this study.
CoQ10 diet preparation
A dose of 1 mg CoQ10/kg body weight per day was used in
this study, which was administered via the diet (18). This was
achieved by appropriate CoQ10 supplementation of laboratory
feed pellets, as we described previously (18, 19). Diet was
prepared twice a week throughout the study.
CoQ10, lipid profile, glucose, and insulin analysis
Total liver ubiquinone (CoQ9 and CoQ10) was quantified by
reverse-phase HPLC with UV detection at 275 nm, as described
previously (18, 19). Serum was obtained as detailed previously
(18), and blood from the tail vein collected into EDTA tubes
and centrifuged for 3 min at 3000 rpm at 48 Celsius to isolate
plasma. Fasted blood glucose measurements were obtained by
using a glucose analyzer (Hemocue). The serum lipid profile
and fasted plasma insulin analyses were performed by using an
auto-analyzer (the Wellcome Trust–supported Cambridge Mouse
Laboratory). Liver triglyceride concentrations were determined
by using the Folch assay (23). Briefly, liver samples were ho-
mogenized in a 2:1 ratio of chloroform:methanol. The distinct
lipid phase was removed after centrifugation, and lipid weight
was quantified after the solvent was removed by evaporation.
Histologic assessment
Liver samples were fixed in formalin, paraffin-embedded,
and sectioned to a 6-mm thickness by using a microtome. Picro
Sirius Red staining was used to stain for fibrosis. Cell-D soft-
ware (Olympus Soft Imaging Solutions) was used to quantify
the thickness of fibrosis around all visible hepatic vessels (in-
cluding all arteries and veins) from 1 section per sample. This
sample was taken at the same point (20 sections for each
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sample) by using a nonbiased grid sampling method. All anal-
yses were performed at 103 magnification by using an Olympus
microscope (Olympus Soft Imaging Solutions). All analyses
were performed blinded.
Mitochondrial electron transport chain complex activities
Activities of complex I [NAD(H): ubiquinone reductase;
Enzyme Commission (EC) 1.6.5.3], complexes II–III (succinate:
cytochrome c reductase; EC 1.3.5.1 + EC 1.10.2.2), and com-
plex IV (cytochrome oxidase; EC 1.9.3.1) as well as citrate
synthase (EC 1.1.1.27) were assayed as described previously
(18, 19).
Protein analysis
Protein was extracted and assayed as described previously
(18). Protein (20 mg) was loaded onto 10%, 12%, or 15%
polyacrylamide gels, dependent on the molecular weight of the
protein to be measured. The samples were electrophoresed and
transferred to polyvinylidene fluoride membranes (18) and de-
tected with the use of the following dilutions of primary anti-
body: insulin receptor substrate 1 (IRS-1; 1:1000; Millipore);
phosphoinositide-3-kinase, p110-b (p110-b); insulin receptor b
(IR-b); protein kinase-z (1:200; Santa-Cruz); Akt-1 and Akt-2
(1:1000; New England Biolabs); phosphoinositide-3-kinase,
p85-a (p85-a; 1:5000; Upstate); cytochrome P450-2E1
(CYP2E1) and Il-6 (1:1000; Abcam); Tnf-a (1:1000; Cell Sig-
naling Technology); and anti-rabbit IgG secondary antibodies
(1:20,000; Jackson Immunoresearch Laboratories). Equal protein
loading was confirmed by staining electrophoresed gels with
Coomassie Blue (Bio-Rad) to visualize total protein.
Gene expression
RNA was extracted by using a miReasy mini kit (Qiagen)
following the manufacturer’s instructions, as detailed previously
(19). A DNase digestion step was performed to ensure no ge-
netic DNA contamination. RNA (1 mg) was used to synthesize
complementary DNA by using oligo-dT-adaptor primers and
Moloney murine leukemia virus reverse transcriptase (Prom-
ega). Gene expression was determined by using custom-
designed primers (Sigma) and SYBR Green reagents (Applied
Biosystems). Primer sequences are presented in Table 1.
Quantification of gene expression was performed with the use of
a Step One Plus reverse transcriptase–polymerase chain reaction
machine (Applied Biosystems). Equal efficiency of the reverse
transcription of RNA from all groups was confirmed through
quantification of expression of the housekeeping gene b-actin
(Actb). The expression of Actb did not differ between groups
(effect of maternal diet, P = 0.9; effect of CoQ10 supplementa-
tion, P = 0.8; control: 153 6 32; recuperated: 144 6 24; control
CoQ10: 143 6 12; and recuperated CoQ10: 157 6 21 average
copy numbers).
Mitochondrial DNA copy number
Total DNAwas extracted using a phenol/chloroform extraction
protocol (24). Mitochondrial DNA copy number analysis was
performed as described previously (25).
4-Hydroxynonenal and 3-nitrotyrosine analysis
Protein nitrotyrosination was assayed by using a Nitrotyrosine
ELISA kit (MitoSciences), according to the manufacturer’s
instructions. Lipid peroxidation was analyzed by using an Oxi-
Select HNE Adduct ELISA kit (Cambridge Biosciences), ac-
cording to the manufacturer’s instructions.
Statistical analysis
Data were analyzed by using a 2-factor ANOVAwith maternal
diet and CoQ10 supplementation as the independent variables.
Post hoc testing was carried out when appropriate and is in-
dicated in the text accordingly. Data are represented as means 6
SEMs. All statistical analyses were performed with the use of
Statistica 7 software (Statsoft), and for all tests, P values ,0.05
were considered significant. Data were checked for normal
distribution. In all cases, “n” refers to the number of litters (with
1 rat used from each litter).
RESULTS
Anthropometric measurements
Recuperated offspring were born smaller than control rats
(6.3 6 0.2 compared with 7.4 6 0.2 g; P , 0.001) and un-
derwent rapid postnatal catch-up growth so that their weights
were similar to those of the control offspring at postnatal day 21
(52.26 0.9 compared with 50.76 1.2 g). At 12 mo of age, there
was no effect of maternal diet or CoQ10 supplementation on
body weights or absolute liver weights (Table 2).
Dietary CoQ10 supplementation leads to greater hepatic
CoQ9 and CoQ10 concentrations
Recuperated hepatic CoQ9 and CoQ10 concentrations were
unaltered compared with those in control rats (Table 3). How-
ever, CoQ9 and CoQ10 concentrations were greater (P , 0.01)
when supplemented with CoQ10 (Table 3).
CoQ10 supplementation ameliorates hepatic fibrosis and
inflammation induced by poor maternal nutrition
Recuperated offspring showed greater (P , 0.001) collagen
deposition (Figure 1A) than did control offspring (Figure 1B,
C). CoQ10 supplementation prevented this effect of maternal diet
(P , 0.001; interaction between maternal diet and CoQ10 sup-
plementation, P = 0.001) (Figure 1A, D, E). Collagen type 1, a1
(Col1a1), mRNA expression was also greater (P , 0.05) in
recuperated offspring (Figure 1F) and was reduced (P , 0.05)
by CoQ10 supplementation (interaction between maternal diet
and CoQ10 supplementation, P = 0.001) (Figure 1F).
Recuperated and control offspring had similar expression of
the profibrotic cytokine transforming growth factor b1 (Tgfb1),
and a trend for greater expression of monocyte chemoattractant
protein 1 (Mcp1; effect of maternal diet, P = 0.06) was observed
in recuperated offspring (Figure 2A). CoQ10 supplementation
reduced the concentrations of Tgfb1 (effect of CoQ10 supple-
mentation, P , 0.001) and Mcp1 (effect of CoQ10 supplemen-
tation, P = 0.07) (Figure 2A). The cytokine Tnf-a was greater
in recuperated offspring than in controls (effect of maternal
diet, P , 0.05) and concentrations were reduced by CoQ10
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supplementation (effect of CoQ10 supplementation, P , 0.05).
Concentrations of Il-6 were greater (P , 0.05) in recuperated
offspring than in controls and this effect was prevented by
CoQ10 supplementation (P , 0.001; interaction between ma-
ternal diet and CoQ10 supplementation, P , 0.001) (Figure
2B). The gene expression of markers of hepatic stellate cell
(HSC) and Kupffer cell (KC) activation [a-smooth muscle
actin 2 (Acta2), desmin (Des), and C-type lectin-domain
family 4 (Clec4f)] was greater in recuperated offspring than in
controls (effects of maternal diet, P , 0.05 for all listed var-
iables) (Figure 2C). CoQ10 supplementation reduced Des (P ,
0.001), Clec4f (P , 0.05), and cluster of differientation 68
(Cd68) (P , 0.01; all were effects of CoQ10 supplementation)
(Figure 2C). Acta2 was unchanged by CoQ10 supplementation
(Figure 2C). Glial fibrillary acidic protein (Gfap) mRNA ex-
pression was not significantly different between groups (Figure
2C). Gene expression of matrix metalloproteinase (Mmp) 9
(Mmp9) was greater (P , 0.01) in recuperated offspring than
in controls, and CoQ10 supplementation reduced (P , 0.001)
recuperated Mmp9 mRNA to control levels (interaction be-
tween maternal diet and CoQ10 supplementation, P , 0.05)
(Figure 2D). The gene expression of Mmp2 remained unaltered
between groups (Figure 2D). Tissue inhibitors of Mmps
(Timps) were also not significantly different between groups
(Figure 2E).
CoQ10 supplementation attenuates ROS induced by poor
maternal nutrition
Components of the NAD(P)H oxidase 2 (NOX-2) protein
complex—Gp91phox (P , 0.05), P22phox (P , 0.05), and
P47phox (P = 0.05)—were greater in recuperated offspring than
in controls. P67phox was greater (P , 0.01) in recuperated off-
spring than in controls, and this effect was reduced (P , 0.001)
TABLE 1
Primers1
Sequence
Primer F R Product size, bp
Col1a1 GCCTCCCAGAACATCACCTA GCAGGGACTTCTTGAGGTTG 82
Tgfb TGCCCTCTACAACCAACACA CTTGCGACCCACGTAGTAGA 100
Mcp1 TGGACCAGAACCAAGTGAGA TGCTGAAGTCCTTAGGGTTGA 71
Acta2 GACATCAGGAAGGATCTCTATGC TCTCCTTCTGCATCCTGTCA 88
Des GGAGGAGATCCGACACCTAA ACATCCAAGGCCATCTTCAC 87
Gfap GAGTTACCAGGAGGCACTCG GGGCCATCTCCTCCTTGAG 65
Clec4f ACGGAGAGCGTGAAGACTGT CTTGCACACCCAGTTGTAGG 83
Cd68 AAAGCTTCTGTTGCGGAAAT GAGCAGGTCCAGGTGAATTG 62
Mmp2 GGAAAGAGGATACCCCAAGC TCCAGTTAAAGGCAGCGTCT 80
Mmp9 TTGGGTCTAGGCTCAGAGGT AGATACGTTCCCGGCTGAT 88
Timp1 CTGAGAAGGGCTACCAGAGC TATTGCCAGGTGCACAAATC 70
Timp2 GGATGGACTGGGTCACAGAG GCGCAAGAACCATCACTTCT 85
Gp91phox CGAAGCCTTGGCTAAAACTCT TCCTTGTTGAAGATGAAGTGGA 87
P22phox GTGAGCAGTGGACTCCCATT GTAGGTGGCTGCTTGATGGT 76
P47phox TGTGACACCCTCTCACAGACA GTCGCATTTTCCCTCCTTTA 96
P67phox CCGATAACCGGACAACAGAG CAGGTCTTCTGGCTGGGTAG 72
P40phox GATGTGGGACTCATGGTGAA AATTGTCCTTCTGGGTGACG 91
Nrf2 AGCAAGACTTGGGCCACTTA GATGGAGGTTTCTGTCGTTTTC 78
Hmox1 TAACCAGGATCTCCCCAAGA TTAGAGTGCTGTGGCAGGTG 73
Gpx1 CACCCGCTCTTTACCTTCCT CGGGGACCAAATGATGTACT 75
Gst TCTTGTTGGCAACCAACTCA AGTCAGACAGCACAGGAGCA 92
Nqo1 TGGAGACTGTCTGGGAGGAG TCCTGCCTGGAAGTTTAGGT 74
Actb ATGCTGCGTCTGGACTG CTCCAGTGTGGTGAA 85
1Acta2, a-smooth muscle actin 2; Actb, b-actin; Cd68, cluster of differentiation 68; Clec4f, C-type lectin-domain
family 4; Col1a1, collagen type 1, a1; Des, desmin; F, forward; Gfap, glial fibrillary acidic protein; Gpx1, glutathione
peroxidase 1; Gst, glutathione synthetase; Hmox1, heme oxygenase 1; Mcp1, monocyte chemoattractant protein 1; Mmp,
matrix metalloproteinase; Nqo1, NAD(P)H dehydrogenase, quinone 1; Nrf2, nuclear factor, erythroid 2–like 2; R, reverse;
Tgfb, transforming growth factor b; Timp, tissue inhibitor of matrix metalloproteinases.
TABLE 2
Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on rat pup body and liver
weights1
Control Recuperated Control CoQ10 Recuperated CoQ10
Body weight at 12 mo, g 956.3 6 25.2 920.3 6 28.8 979.6 6 35.1 935.7 6 29.9
Absolute liver weight at 12 mo, g 27.5 6 1.4 28.4 6 1.2 28.1 6 1.2 29.5 6 1.3
1Values are means 6 SEMs; n = 10/group. Data were analyzed by using 2-factor ANOVA and Duncan’s post hoc
testing, where appropriate. No significant differences between groups were reported. CoQ10, coenzyme Q.
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by CoQ10 supplementation (interaction between maternal diet
and CoQ10 supplementation, P , 0.01) (Figure 3A). Levels of
Gp91phox (P = 0.08), P22phox (P , 0.001), and P47phox
(P = 0.05) were reduced by CoQ10 supplementation (Figure 3A).
CYP2E1 was not significantly different between control and
recuperated offspring; however, CoQ10 supplementation reduced
this concentration by 50% (effect of CoQ10 supplementation,
P , 0.01) (Figure 3B). Complex I and complex IV electron
transport chain activities were greater in recuperated offspring
(effect of maternal diet, P = 0.05); however, complex II–III
activity was unaffected. CoQ10 supplementation caused an
increase in complex IV activity (effect of CoQ10 supplemen-
tation, P , 0.05) (Figure 3C). Mitochondrial DNA copy
number was not significantly different between groups (con-
trol: 36 6 4 copy numbers; recuperated: 36 6 5 copy numbers)
or by CoQ10 supplementation (control CoQ10: 41 6 4 copy
numbers; recuperated CoQ10: 35 6 3 copy numbers). Con-
centrations of 4-hydroxynonenal (4-HNE) adducts were greater
(P , 0.05) in recuperated offspring. There was a significant
interaction between maternal diet and CoQ10 supplementation
on 4-HNE concentrations (P , 0.05), reflecting the fact that
CoQ10 supplementation reduced 4-HNE concentrations in re-
cuperated offspring but had no effect in control offspring
(Figure 3D). 3-nitrotyrosine concentrations were not signifi-
cantly different between groups (Figure 3E).
CoQ10 supplementation alters hepatic antioxidant defense
capacity
Nuclear factor erythroid 2–like 2 (Nrf2), heme oxygenase 1
(Hmox1), and glutathione synthetase (Gst) expression were not
significantly different between control and recuperated off-
spring (Figure 4A, B). Glutathione peroxidase 1 (Gpx1) was
reduced in recuperated offspring compared with controls, and
this effect was prevented by CoQ10 supplementation (in-
teraction between maternal diet and CoQ10 supplementation,
P , 0.05). NAD(P)H dehydrogenase, quinone 1 (Nqo1), was
reduced in recuperated offspring (effect of maternal diet, P ,
0.05) (Figure 4A, B). CoQ10 supplementation increased Nrf2
(P , 0.001), Hmox1 (P , 0.05), and Gst (P , 0.001) (Figure
4A, B); however Nqo1 expression was reduced by CoQ10
supplementation (effect of CoQ10 supplementation, P , 0.001)
(Figure 4A).
CoQ10 supplementation alters expression of molecules
involved in insulin and lipid metabolism
Greater serum insulin concentrations were observed in re-
cuperated offspring than in controls (overall effect of maternal
diet, P , 0.05) (Figure 5A). Concentrations were reduced by
CoQ10 supplementation (effect of CoQ10 supplementation,
P , 0.01) (Figure 5A). Protein expression of IR-b (P ,
0.001), IRS-1 (P , 0.001), and Akt-1 (P , 0.05) was reduced
in recuperated offspring compared with controls (all effects of
maternal diet). Phosphoinositide-3-kinase-p110-b (p110-b),
phosphoinositide-3-kinase-p85a (p85-a), and Akt-2 were not
influenced by maternal diet (Figure 5B). CoQ10 supplemen-
tation increased p110-b (P , 0.05) and Akt-2 (P , 0.01)
protein expression (Figure 5B). Fasting plasma glucose con-
centrations were not significantly different between groups
(Table 3). Serum and hepatic triglyceride concentrations and
serum cholesterol concentrations were not significantly dif-
ferent between control and recuperated offspring (Table 3).
CoQ10 supplementation increased serum triglyceride and
cholesterol concentrations (effects of CoQ10 supplementation,
P , 0.05); however, hepatic triglyceride concentrations were
unchanged (Table 3).
DISCUSSION
Our findings that a maternal low-protein diet in utero followed
by accelerated postnatal growth (recuperated) confers a higher
risk of oxidative damage, proinflammatory changes, and liver
fibrosis suggest that the early environment is an important de-
terminant of an individual’s risk of developing complications of
fatty liver disease. The potential for progression from NAFLD to
nonalcoholic steatohepatitis and finally to hepatitis, fibrosis, and
cirrhosis is well described. However, it has not previously been
possible to identify patients who are at high risk of these
changes. Our finding that recuperated rats developed more he-
patic fibrosis than did controls indicates that the early environ-
ment plays a central role in the risk of liver disease in later life.
Identifying the early environment as influential in the propensity
to hepatic inflammation and fibrosis provides valuable new in-
sight into predetermining individuals at increased risk from
hepatic manifestations of the metabolic syndrome.
HSCs are the main source of extracellular matrix formation
during hepatic fibrosis (26). The key step in inducing fibrosis during
TABLE 3
Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on serum and plasma
measurements1
Control Recuperated
Control
CoQ10
Recuperated
CoQ10
Effect of
CoQ10
Hepatic CoQ9, pmol/mg protein 494 6 28 497 6 24 872.4 6 79** 1071 6 266** 0.003
Hepatic CoQ10, pmol/mg protein 80 6 7 78 6 6 146 6 17** 102 6 11** 0.002
Fasting plasma glucose, mmol/L 5.6 6 0.2 5.3 6 0.1 5.4 6 0.3 5.24 6 0.2 0.9
Serum cholesterol, mmol/L 4.8 6 0.5 4.9 6 0.4 6.1 6 0.7* 5.9 6 0.6* 0.04
Serum trigyclerides, mmol/L 3.8 6 0.05 3.8 6 0.4 4.2 6 0.6* 5.7 6 0.7* 0.02
Hepatic triglyceride content, g 2.0 6 0.2 2.3 6 0.2 2.0 6 0.1 2.0 6 0.2 0.3
1Values are means 6 SEMs; n = 10/group. Data were analyzed by using 2-factor ANOVA and Duncan’s post hoc
testing, where appropriate. The overall effects of maternal diet and interaction between maternal diet and CoQ10 supple-
mentation were not significant for any of the variables reported in the table. *,**Effect of CoQ10: *P , 0.05, **P , 0.01.
CoQ10, coenzyme Q.
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liver injury is the transformation of quiescent HSCs to activated
HSCs, which differentiate into myofibroblasts (26). We found in-
creased expression of Acta2 and Des in recuperated offspring.
Acta2 is expressed in myofibroblasts of damaged liver (27) and
hence is a good marker of HSC activation. In rats, HSC activation
and proliferation correlate with a high expression of Des and are
FIGURE 1 Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on hepatic fibrosis, quantified by
measurement of collagen (A), in 12-mo-old male rat livers (B–E). (F) mRNA expression of Col1a1. Values are as means 6 SEMs; n = 10/group;
10/10 rats used. *,***C compared with R and R compared with RQ: *P , 0.05, ***P , 0.001. Interaction between in utero protein restriction,
accelerated postnatal growth, and CoQ10 supplementation (statistical interaction): P = 0.001 (A and F). Data were analyzed by using 2-factor ANOVA
and Duncan’s post hoc testing, where appropriate. C, control; Col1a1 = collagen type 1, a1; CoQ10, coenzyme Q; CQ, control CoQ10; R, recuperated;
RQ, recuperated CoQ10.
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found in HSCs of acutely injured liver (27). KC infiltration and
activation play a prominent role in HSC activation. Increased KC
infiltration coincides with the activation of HSC markers such as
Acta2 (28). Cle4f (a unique KC receptor for glycoproteins and
therefore a good marker of KC activation) was increased in livers
of recuperated offspring.
Increased concentrations of proinflammatory cytokines are
also crucial in initiating HSC activation. Hepatic protein ex-
pression of Tnf-a and Il-6 was greater in recuperated offspring,
suggesting that inflammation plays a role in the HSC activation
and consequent hepatic fibrosis observed in our model. Tgfb1
mRNA levels were not changed in recuperated offspring;
however, we cannot discount the possibility that Tgfb1 is up-
regulated at the protein level. Mcp1 (a chemokine that acts as
a chemoattractant for HSCs) was also upregulated in re-
cuperated livers. Mmps are also associated with hepatic fi-
brosis (29). Mmp9 expression was upregulated in recuperated
livers. Mmp9 is prominent in scar areas of active fibrosis, and
treatment with a profibrotic agent can increase its expression,
with peak expression coinciding with induction of inflamma-
tory cytokines (29). Mmp2 expression was unaltered between
groups. Because Mmp expression is an early event in wound
healing, the time window for Mmp2 elevation may have been
missed and that difference would be observed only in younger
animals.
A further driving factor in HSC activation and fibrosis is
increased ROS, which can be generated by Tnf-a, Il-6 (30),
KCs (28), and the mitochondrial electron transport chain. We
found increased ROS in the context of increased lipid perox-
idation [which is known to increase in liver disease (31)] and
greater expression of the NOX-2 components (Gp91phox,
P22phox, P47phox, and P67phox), a major source of hepatic ROS
production, which have been observed in hepatic fibrosis (32,
33). Complex I activity, a predominant generator of ROS (34),
was greater in recuperated livers. Decreased antioxidant de-
fense capacity was evidenced by a reduction in Gpx1, a per-
oxidase responsible for the conversion of H2O2 into H2O and
O2. Increased concentrations of cellular H2O2, due to Gpx1
FIGURE 2 Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on inflammatory markers Tgfb1 and Mcp1
mRNA (A), Tnf-a and Il-6 protein (B), mRNA expression of markers of HSC activation (Acta2, Des, Gfap) and KC activation (Clec4f, Cd68) (C), and Mmp
(D) and Timp (E) mRNA in 12-mo-old male rat livers. Values are means 6 SEMs; n = 10/group; 10/10 rats used. **,***C and R compared with CQ and RQ:
**P , 0.01, ***P , 0.001. *,**C compared with R: *P , 0.05, **P , 0.01. ***R compared with RQ, P , 0.001. Statistical interactions: Tgfb1, P = 0.1;
Mcp1, P = 0.3; Tnf-a, P = 0.5; Il-6, P = 0.002; Acta2, P = 0.5; Des, P = 0.3; Gfap, P = 0.5; Clec4f, P = 0.1; Cd68, P = 0.9; Mmp2, P = 0.9; Mmp9, P = 0.04;
Timp1, P = 0.6; Timp2, P = 0.8. Data were analyzed by using 2-factor ANOVA and Duncan’s post hoc testing, where appropriate. Acta2, a-smooth muscle
actin 2; C, control; Cd68, cluster of differentiation 68; Clec4f, C-type lectin-domain family 4; Col1a1, collagen type 1, a1; CoQ10, coenzyme Q; CQ, control
CoQ10; Des, desmin; Gfap, glial fibrillary acidic protein; Mcp1, monocyte chemoattractant protein 1; Mmp, matrix metalloproteinase; R, recuperated; RQ,
recuperated CoQ10; Tgfb1, transforming growth factor b1; Timp, tissue inhibitor of matrix metalloproteinase.
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depletion, could cause accumulation of the hydroxyl anion,
a free radical that can directly increase lipid peroxidation.
Accumulation of hepatic triglycerides also plays a role in
hepatic fibrosis (35); however, neither liver nor plasma tri-
glycerides were altered in recuperated rats. This may be ex-
plained by the fact that recuperated offspring are fed a feed pellet
diet and do not display an obesogenic phenotype. This in itself is
interesting, because it shows that the observed deleterious liver
phenotypes develop in a physiologic environment that had been
influenced only by developmental programming per se, and not
by obesity.
Insulin resistance and hyperinsulinemia are also major
contributors to liver fibrosis (36) and are inherently linked to
increased oxidative stress. Recuperated offspring had whole-
body insulin resistance as indicated by hyperinsulinemia. The
hyperinsulinemia was associated with hepatic insulin signaling
protein dysregulation, as shown by the downregulation of IR-b,
IRS-1, and Akt-1.
Importantly, we identified an effective means of arresting the
pathologic progression of NAFLD, by postnatal supplementa-
tion with CoQ10. In recuperated offspring, CoQ10 supplemen-
tation reduced markers of HSC and KC activation, the
accumulation of ROS, and the deposition of collagen around
the hepatic vessels. This agrees with a study in which high-fat
diet fed mice administered 1% CoQ10 supplementation led to
reduced hepatic NOX expression (37). CoQ10 supplementation
also increased activity of complex IV, in keeping with in vitro
studies (38). CoQ10 supplementation decreased Tnf-a, Il-6,
Tgfb1, and Mcp1, suggesting that CoQ10 also can reduce in-
flammatory changes in liver, which is consistent with studies in
FIGURE 3 Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on indexes of oxidative stress: components of
the NOX-2 complex (A), CYP2E1 (B), ETC activities (C), 4-HNE (D), and 3-NT adducts (E) in 12-mo-old male rat livers. Values are means 6 SEMs; n =
10/group; 10/10 rats used. D: *Comparison of C with R and comparison of R with RQ, P , 0.05. A and B: **Comparison of C with R, P , 0.01;
***Comparison of R with RQ and comparison of C and R with CQ and RQ, P , 0.001. Statistical interactions: NOX-2 (Gp91phox, P = 0.5; P22phox, P = 0.3;
P47phox, P = 0.4; P67phox, P = 0.01; P40phox, P = 0.3), CYP2E1 (P = 0.5), ETC activities (complex I, P = 0.9; complexes II–III, P = 0.6; complex IV, P = 0.9),
4-HNE (P = 0.04), and 3-NT (P = 0.8). Data were analyzed by using 2-factor ANOVA and Duncan’s post hoc testing, where appropriate. C, control; CoQ10,
coenzyme Q; CQ, control CoQ10; CS, citrate synthase; CYP2E1, cytochrome P450-2E1; ETC, electron transport chain; NOX-2, NAD(P)H oxidase 2; R,
recuperated; RQ, recuperated CoQ10; 3-NT, 3-nitrotyrosine; 4-HNE, 4-hydroxynonenal.
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mouse liver (37) and human blood (39). Our data therefore
recapitulate CoQ10’s function, both as a potent antioxidant (15)
and as an anti-inflammatory agent.
CoQ10 supplementation also prevented hyperinsulinemia
in recuperated rats; however, hepatic insulin signaling pro-
tein dysregulation was not normalized by CoQ10 supple-
mentation. The whole-body insulin sensitivity may therefore
be improved through other mechanisms such as improve-
ments in muscle and/or adipose tissue insulin sensitivity.
CoQ10 may exert antifibrotic effects through the activation
of the Nrf2/antioxidant response element (Nrf2/ARE) path-
way. Nrf2 is a transcription factor that responds to oxidative
status and regulates transcription of genes involved in an-
tioxidant defense. CoQ10 treatment in a model of hepatic
fibrosis ameliorates liver damage via suppression of Tgfb1
and upregulation of Nrf-ARE-associated genes (40). Al-
though Nrf2 expression was not affected by maternal diet,
CoQ10 supplementation increased Nrf2 by 4-fold. The anti-
oxidant genes involved in the Nrf2/ARE pathway—Hmox1,
Gst, and Gpx1—were increased by CoQ10 supplementation.
This suggests that CoQ10 supplementation upregulates the
Nrf2/ARE pathway via suppression of Tgfb1 (40). These
observations support a role for CoQ10 supplementation in
increasing antioxidant defenses to a protective level in an-
imals that have experienced detrimental catch-up growth
(18, 19). Because Nqo1 activity is known to prevent 1
electron reduction in quinones, it is plausible that because
hepatic CoQ10 concentrations are elevated by CoQ10 sup-
plementation, Nqo1 expression is not required and thus
suppressed.
In conclusion, a suboptimal early-life environment combined
with a mismatched postnatal milieu predisposes offspring to
increased hepatic ROS, inflammation, and hyperinsulinemia,
leading to hepatic fibrosis. This recapitulates changes seen in
patients in whom benign NAFLD progresses to cirrhosis and
ultimately liver failure. We suggest that the early environment
life is crucial in identifying the subgroup of patients at highest
risk of such progression; however, this should be tested in
humans. A clinically relevant dose of CoQ10 reversed liver fi-
brosis via downregulation of ROS, inflammation, and hyper-
insulinemia and upregulation of the Nrf2/ARE antioxidant
pathway. Because fibrosis contributes to up to 45% of deaths in
the industrial world (41), CoQ10 supplementation may be
a cost-effective and safe way of reducing this global burden
in at-risk individuals, before the development of an NAFLD
phenotype.
FIGURE 4 Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on mRNA expression of molecules involved in
the NRF antioxidant defense pathway in 12-mo-old male rat livers. (A) Nrf2, Hmox1, and Nqo1 and (B) Gst and Gpx1. Values are means 6 SEMs; n = 10/
group; 10/10 rats used. *,***C and R compared with CQ and RQ: *P , 0.05, ***P , 0.001. *C compared with R and C compared with CQ, P , 0.05.
***R compared with RQ, P , 0.001. Statistical interactions: Nrf2, P = 0.9; Hmox1, P = 0.6; Nqo1, P = 0.4; Gst, P = 0.1; Gpx1, P = 0.01. Data were analyzed
by using 2-factor ANOVA and Duncan’s post hoc testing, where appropriate. C, control; CoQ10, coenzyme Q; CQ, control CoQ10; Gpx1, glutathione
peroxidase 1; Gst, glutathione synthetase; Hmox1, heme oxygenase 1; Nqo1, NAD(P)H dehydrogenase, quinone 1; NRF, nuclear erythroid 2-related factor;
Nrf2, nuclear factor, erythroid 2–like 2; R, recuperated; RQ, recuperated CoQ10.
FIGURE 5 Effect of in utero protein restriction, accelerated postnatal growth, and CoQ10 supplementation on serum insulin (A) and insulin
signaling protein expression (B) in 12-mo-old male rat livers. Values are means 6 SEMs; n = 10/group; 10/10 rats used. Statistical interactions:
insulin, P = 0.3; insulin signaling proteins (IR-b, P = 0.12; IRS-1, P = 0.5; p110b, P = 0.4; p85a, P = 0.3; Akt-1, P = 0.05; Akt-2, P = 0.5). Data were
analyzed by using 2-factor ANOVA and Duncan’s post hoc testing, where appropriate. C, control; CoQ10, coenzyme Q; CQ, control CoQ10; IR-b,
insulin receptor b; IRS-1, insulin receptor substrate 1; p85a, phosphoinositide-3-kinase, p85-a; p110-b, phosphoinositide-3-kinase, p110-b; R, re-
cuperated; RQ, recuperated CoQ10.
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